

**ASX ANNOUNCEMENT**

21 September 2022

**Cleansing notice under  
section 708A(5)(e) of the Corporations Act 2001 (Cth)**

Reference is made to the Appendix 2A released to ASX on 21 September 2022 relating to the issue of 60,000 fully paid ordinary shares (**New Shares**) by Kazia Therapeutics Limited ACN 063 259 754 (**KZA**).

**Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)**

For the purposes of section 708A(6) of the Corporations Act 2001 (Cth) (**Corporations Act**), KZA advises as follows:

1. The New Shares were issued without disclosure under Part 6D.2 of the Corporations Act.
2. This notice is given under section 708A(5)(e) of the Corporations Act.
3. As at the date of this notice, KZA has complied with:
  - (a) the provisions of Chapter 2M of the Corporations Act as they apply to KZA; and
  - (b) section 674 of the Corporations Act.
4. As at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act.

Authorised for release by the Board of Directors.

Signed for and on behalf of KZA



Kate Hill  
Company Secretary